Teva制药公司合作伙伴将AHZANTIVE商业化,AHZANTIVE是欧洲和以色列Eylea的生物类似物。 Teva Pharmaceuticals partners to commercialize AHZANTIVE, a biosimilar of Eylea, in Europe and Israel.

Teva制药公司与Klinge Biopharma公司和Formycon AG公司合作,在欧洲和以色列(意大利除外)将一种生物相似的Eylea(Aflibertya)商业化。 Teva Pharmaceuticals has partnered with Klinge Biopharma and Formycon AG to commercialize a biosimilar version of Eylea (aflibercept) in Europe and Israel, excluding Italy. 这一合作扩大了Teva的生物类比组合,利用了Teva的分销和销售网络以及Formycon的药物开发能力。 This collaboration, which expands Teva's biosimilars portfolio, leverages Teva's distribution and sales network and Formycon's drug development capabilities. 生物类同的标有AHZANTIVE,预计不久将获得管制批准。 The biosimilar, branded AHZANTIVE, is expected to receive regulatory approval soon. 这一伙伴关系是继自2015年以来在另一类类似生物上成功合作之后建立起来的。 This partnership follows a successful collaboration on another biosimilar since 2015.